Aardvark Therapeutics (AARD) Times Interest Earned (2024 - 2025)

Aardvark Therapeutics (AARD) reported Times Interest Earned of -$990.5 for Q2 2025, up 90.54% sequentially from -$10470.0 in Q1 2025.

Aardvark Therapeutics (AARD) Times Interest Earned (2024 - 2025) Analysis & Trends

Aardvark Therapeutics (AARD) has 2 years of Times Interest Earned data on file, last reported at -$990.5 in Q2 2025.

For the quarter ending Q2 2025, Times Interest Earned changed N/A year-over-year to -$990.5; the trailing twelve-month figure through Jun 2025 stood at -$2553.7 (changed N/A YoY), and the FY2025 full-year result was -$5.07, down 310.62% from the prior year.
Times Interest Earned grew to -$990.5 in Q2 2025, from -$10470.0 in the prior quarter.
In the past five years, Times Interest Earned ranged from a high of -$2.98 in Q4 2024 to a low of -$10470.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	658.42
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.60
4	NuCana	279.75 Bn	279.75 Bn	-	-0.22
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.71
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	22.72
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-0.38
10	Aardvark Therapeutics	139.40 Mn	19.44 Mn	-	-

Download Data